101-金老师-XXXX0523仿制药一致性评价的机遇和挑战

¾¾¾¾¾¾¾¾•–4mg8mg•–2ml4mg2ml8mg•–250ml4mg12.5g•–250ml4mg25g–250ml4mg2.5g10010030•1↑0.3%30•↑2.3%•1115•1↑4.0%•11530↑•↑4.0%•121•1↑4.3%↑44%15•↑4.4%CH3NCH3H3CHOH3CHONOHCH3OCH3OCH3H3COOCH3HOH3CH3CHOOHOHOCH3OOH3COHCH3H3CAzithromycinAHPLC4)4)ALT1003490¾149.5%~74.9%2742274.234.2A1A1224004006070~8055~65OHOOHOH-H2OOOOHOHOH+280.1S92.2H2O206.2OHOOOOOOHOHOHOH+4471T)92.2-2H2O206.22447.1T)µµµµµµ241415OIIOHNH2HOOCOIIOHNH2HOOCIIC15H11I4NO4IC15H12I3NO4151234(3,5,3-triiodothyronine,T3)(3,5,3′,5′-tetraiodothyronine,T4)(42010µµ0.2550.345/HPLCUV65mg110mg240mg360mgµµ5T3T4T3μgT4μg56212690%110%17918994.7%/40/40T3μg/40mgT4μg/40mgAYG09090114.9569.1BYG09080414.7469.78AB14.7469.78C/14.0767.28DYG09090313.5465.01EB/8.4441.52B.180100120J.PpH1.2204060%J.PpH4.0J.PpH6.8J.Pshui030min60min2h4h6h8h1224hH¾¾¾223CH3CH3H3CH3CNCH312OCH3OCH3H3COOCH3NCH3H3CHOH3CHOOHOHOCH3OOH3COHCH3OCH3H3CAihiAAzithromycinAβ-¾¾9999¾¾9999¾¾¾¾¾¾¾¾¾¾¾¾¾¾•••••¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾99¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾12344